Biogen (XSWX:BIIB) Long-Term Debt: CHF4,951 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIIB Biogen Inc XSWX:BIIB
74 GF Score
Price CHF173.46
GF Value CHF164.93
! 7 Warning Signs
View Full Analysis

What is Biogen Long-Term Debt?

Biogen XSWX:BIIB 74 Long-Term Debt is CHF4,951 Mil as of Mar. 2026. GuruFocus rates XSWX:BIIB with a GF Score™ of 74/100 and a GF Value™ of CHF164.93. The stock has 7 warning signs investors should review.

Biogen's Long-Term Debt for the quarter that ended in Mar. 2026 was CHF4,951 Mil.

Biogen's quarterly Long-Term Debt increased from Sep. 2025 (CHF5,004 Mil) to Dec. 2025 (CHF5,010 Mil) but then declined from Dec. 2025 (CHF5,010 Mil) to Mar. 2026 (CHF4,951 Mil).

Biogen's annual Long-Term Debt declined from Dec. 2023 (CHF5,870 Mil) to Dec. 2024 (CHF4,054 Mil) but then increased from Dec. 2024 (CHF4,054 Mil) to Dec. 2025 (CHF5,010 Mil).

Biogen  (XSWX:BIIB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Biogen Long-Term Debt Related Terms

Biogen Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Biogen's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Long-Term Debt Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,778.35 5,851.38 5,870.44 4,054.28 5,009.95

Biogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,019.23 5,109.91 5,003.57 5,009.95 4,950.94
XSWX:BIIB
74GF Score
Biogen Inc XSWX:BIIB
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of CHF4,951 Mil mean?
Biogen (XSWX:BIIB) has a Long-Term Debt of CHF4,951 Mil as of Mar. 2026.
Is Biogen's Long-Term Debt too high?
Biogen's current Long-Term Debt is CHF4,951 Mil. Overall, Biogen has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Biogen's Long-Term Debt compare to OGN and AMRN?
Biogen's Long-Term Debt of CHF4,951 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Biogen's current Long-Term Debt is CHF4,951 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Biogen (XSWX:BIIB) has a current Long-Term Debt of CHF4,951 Mil. The stock's GF Value™ is CHF164.93, compared to a current price of CHF173.46 — trading 5.2% above its estimated fair value. The current Long-Term Debt is CHF4,951 Mil. Biogen's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Biogen (XSWX:BIIB), the current Long-Term Debt is CHF4,951 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (XSWX:BIIB) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of CHF173.46 is trading 5.2% above its estimated GF Value™ of CHF164.93.

Key valuation signals for XSWX:BIIB:

  • Long-Term Debt: CHF4,951 Mil
  • GF Value™: CHF164.93 vs. price of CHF173.46 (5.2% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
74GF Score

Get the complete analysis for XSWX:BIIB

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF173.46
Price
CHF164.93
GF Value